FDA Grants Priority Review for ZEGALOGUE Supplemental Application
The FDA has granted priority review status for the supplemental application of ZEGALOGUE (dasiglucagon hydrochloride) submitted by Zealand Pharma.
Company
Pharmaceutical intelligence for Zealand Pharma with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.